13-July-2009 - Journal of Alzheimer’s Disease Once Again Achieves Significant Impact Factor Increase

Contacts:
George Perry, PhD
Editor-in-Chief, Journal of Alzheimer's Disease
University of Texas at San Antonio, College of Sciences
Tel: +1 210 458 4450
Fax:+1 210 458 4445
E-mail: george.perry@utsa.edu

Astrid Engelen
IOS Press
Tel: +31 20 688 3355
Fax: +31 20 620 3419
E-mail: a.engelen@iospress.nl
URL: www.j-alz.com

Amsterdam, The Netherlands and San Antonio, TX, USA – International publisher IOS Press and the Editors-in-Chief of the Journal of Alzheimer’s Disease (JAD) are pleased to announce that once again there has been a significant increase in the Journal’s Impact Factor, from 4.081 to 5.101 for 2008 according to Thomson Reuters’ Journal Citation Reports 2009. The Journal of Alzheimer’s Disease continues to strengthen and build on its lead as the most prolific and highly cited journal in the Alzheimer’s disease (AD) field. With an Impact Factor of over 5, JAD is now on par with or exceeds the ranking of some of the most established and highly regarded journals in the neurosciences, pathology and biochemistry.

Editors-in-Chief George Perry and Mark A. Smith commented, “As we celebrate JAD’s 10th anniversary this year, it is extremely rewarding to see tangible evidence of theJournal’s continually increasing value to AD researchers and academic physicians. Our primary goal is to promote the understanding of AD by building on the discoveries of the past, advancing research to identify preventive methods and improve treatment and working towards finding a cure. The dedication of the entire editorial board, contributing authors and our publisher, IOS Press, has been the key to the Journal’s success.”

“The Journal of Alzheimer’s Disease is one of our flagship publications,” stated Einar Fredriksson, Director of IOS Press. “It is extremely gratifying to see the impact that this journal is having in the field. As a specialist journal, it is particularly significant that it is ranked among the top journals included in JCR’s Neurosciences category.”

Back to Press Releases